HLA-B*13:01 and the dapsone hypersensitivity syndrome

New England Journal of Medicine

Volumn 369, Issue 17, 2013, Pages 1620-1628

  Zhang, Fu Ren ^a   Liu, H ^a   Irwanto, A ^v,w   Fu, X A ^a   Li, Y ^v   Yu, G Q ^a   Yu, Y X ^a   Chen, M F ^a   Low, H Q ^v   Li, J H ^a   Bao, F F ^a   Foo, J N ^v   Bei, J X ^v   Jia, X M ^x   Liu, J ^a,r   Liany, H ^v   Wang, N ^a   Niu, G Y ^a   Wang, Z Z ^a   Shi, B Q ^a   Tian, H Q ^a   Liu, H X ^a   Ma, S S ^a   Zhou, Y ^a   You, J B ^a   Yang, Q ^a   Wang, C ^a   Chu, T S ^a   Liu, D C ^a   Yu, X L ^a   Sun, Y H ^a   Ning, Y ^b   Wei, Z H ^c   Chen, S L ^a   Chen, X C ^a   Zhang, Z X ^a   Liu, Y X ^a   Pulit, S L ^x,y   Wu, W B ^d   Zheng, Z Y ^e   Yang, R D ^f   Long, H ^f   Liu, Z S ^g   Wang, J Q ^h   Li, M ⁱ   Zhang, L H ^k   Wang, H ^l   Wang, L M ^m   Xiao, P ⁿ   Li, J L ^o   Huang, Z M ^p   Huang, J X ^p   Li, Z ^q   Xiong, L ^t   Yang, J ^t   Wang, X D ^u   Yu, D B ^u   Lu, X M ^a   Zhou, G Z ^a   Yan, L B ^s   Shen, J P ^s   Zhang, G C ^s   Zeng, Y X ^j   De Bakker, P I W ^x,y,z   Chen, S M ^a   Liu, J J ^v,w   more..

^a Shandong Provincial Institute of Dermatology and Venereology   (China)

^b Sichuan Provincial Institute of Dermatology   (China)

^c Hunan Provincial Center for Disease Control and Prevention   (China)

^d Fujian Center for Disease Control and Prevention   (China)

^e Honghe Institute of Dermatology   (China)

^f Wenshan Institute of Dermatology   (China)

^g CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^h Zhejiang Provincial Institute of Dermatology   (China)

ⁱ GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^j SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^k JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^l Department of Laboratory   (China)

^m Jiangxi Institute of Parasitic Diseases   (China)

ⁿ Chongqing Center for Disease Control and Prevention   (China)

^o Guizhou Provincial Center for Disease Control and Prevention   (China)

^p Shen Zhen Center for Chronic Disease Control   (China)

^q SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^r Beijing Tropical Medicine Research Institute   (China)

^s INSTITUTE OF DERMATOLOGY   (China)

^t YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^u Jinan Institute of Metrology   (China)

^v GENOME INSTITUTE OF SINGAPORE   (Singapore)

^w NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^x MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^y UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^z BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; HLA B ANTIGEN; HLA C ANTIGEN; LEPROSTATIC AGENT;

ADULT; AFRICAN; ARTICLE; ASIAN; CHINESE; CONTROLLED STUDY; DRESS SYNDROME; ETHNIC GROUP; EUROPEAN; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENOME ANALYSIS; GENOTYPE; HLA B 13 01 GENE; HLA B GENE; HLA C GENE; HUMAN; INDIAN; JAPANESE; LEPROSY; MAJOR CLINICAL STUDY; MALE; MICA GENE; POLYPHARMACY; POPULATION GENETICS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REPLICATION STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTHEAST ASIAN; DNA SEQUENCE; DRUG COMBINATION; DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION; GENETICS;

ADULT; DAPSONE; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HLA-B ANTIGENS; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84886265139     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1213096     Document Type: Article

References (26)

1. Fromm E, Wittmann J. Derivate des p-nitrophenols. Berichte Deutsch Chem Ges 1908;41:2264-73.
2. Wozel VE. Innovative use of dapsone. Dermatol Clin 2010;28:599-610.
3. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34.
4. Rao PN, Lakshmi TS. Increase in the incidence of dapsone hypersensitivity syndrome - an appraisal. Lepr Rev 2001;72:57-62.
5. Leslie KS, Gaffney K, Ross CN, Ridley S, Barker TH, Garioch JJ. A near fatal case of the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis. Clin Exp Dermatol 2003;28:496-8.
6. Lowe J, Smith M. The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones. Int J Lepr 1949; 17:181-95.
7. Allday EJ, Barnes J. Toxic effects of diaminodiphenylsulphone in treatment of leprosy. Lancet 1951;2:205-6.
8. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012;92:194-9.
9. Tian W, Shen J, Zhou M, Yan L, Zhang G. Dapsone hypersensitivity syndrome among leprosy patients in China. Lepr Rev 2012;83:370-7.
10. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature 2004;428:486.
11. Chen P, Lin J-J, Lu C-S, et al. Carbamazepine- induced toxic effects and HLAB*1502 screening in Taiwan. N Engl J Med 2011;364:1126-33.
12. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43.
13. Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev 1989;60:267-73.
14. Bei JX, Li Y, Jia WH, et al. A genomewide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010;42:599-603.
15. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
16. Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 2007;81: 1084-97.
17. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006;38:1166-72.
18. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:1551-7.
19. Erlich RL, Jia X, Anderson S, et al. Next-generation sequencing for HLA typing of class I loci. BMC Genomics 2011;12: 42.
20. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39: D913-9.
21. Shi L, Xu SB, Ohashi J, et al. HLA-A, HLA-B, and HLA-DRB1 alleles and haplotypes in Naxi and Han populations in southwestern China (Yunnan province). Tissue Antigens 2006;67:38-44.
22. Yang G, Deng YJ, Hu SN, et al. HLA-A, -B, and -DRB1 polymorphism defined by sequence-based typing of the Han population in Northern China. Tissue Antigens 2006;67:146-52.
23. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001;62:1009-30.
24. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012;486:554-8.
25. Bade-Doeding C, DeLuca DS, Seltsam A, Blasczyk R, Eiz-Vesper B. Amino acid 95 causes strong alteration of peptide position P{omega} in HLA-B*41 variants. Immunogenetics 2007;59:253-9.
26. Global leprosy: update on the 2012 situation. Wkly Epidemiol Rec 2013; 88:365-79.